Recent Highlights:

1. Can-Fite announced that due to patient survival, top-line results of the Namodenoson Phase II advanced liver cancer study were expected to be
released in Q1 2019. The statistical plan for this trial requires that the primary efficacy analysis occurs when no more than 3 of the original 78
patients survive. it means, approximately 2 months for results

2. In anticipation of the Phase II liver cancer data release, Can-Fite brought on board Professor Joseph Llovet, a Key Opinion Leader in the field of
liver diseases, founder and director of the Liver Cancer Program and full professor of medicine at the Mount Sinai School of Medicine, New
York University (USA). Professor Llovet will assist in the analysis of the Phase II data that are anticipated in Q1 2019.

3. January 18, 2019 , offered 4,476,192 ordinary shares represented by 2,238,096 American Depositary Shares, or ADSs, to an institutional investor under a
securities purchase agreement.

With two top-line data expected in Q1/2019 and H1/2019 for HCC and NAFLD/NASH, respectively, 2019 will be an awakening year.

Technically, a good things can happen only above MA200 and 1.35.
But how CANF will behave from now to that critical results of PH2?

Follow RSI and MACD :)

I do not recommend selling or buying,
Holding CANF
Home Stock Screener Forex Screener Crypto Screener Economic Calendar Shows How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Refer a friend My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out